<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162473</url>
  </required_header>
  <id_info>
    <org_study_id>09-007320</org_study_id>
    <nct_id>NCT01162473</nct_id>
  </id_info>
  <brief_title>Milk Oral Immunotherapy in Children to Treat Food Allergy</brief_title>
  <official_title>A Study of the Efficacy of Milk Oral Immunotherapy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Rationale

      For patients with Immunoglobulin E (IgE)-mediated food allergy, the current management
      includes identification of the causative food and avoidance. Specifically, among young
      children, cow's milk allergy is the most common food allergy, occurring in as many as 2-3%.
      Given the prevalence of milk and the difficulty to avoid it in the diet, the investigators
      aim to investigate the safety and efficacy of oral immunotherapy for cow's milk allergy.

      Main Objective

      The primary objective is to study the efficacy of milk oral immunotherapy.

      Target Population

      Children aged six to 17 years with a history of cow's milk allergy will be recruited from The
      Children's Hospital of Philadelphia Allergy clinical offices for the investigators study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Study Interventions

      Prior to and after the desensitization, we will conduct double-blind placebo controlled food
      challenges to cow's milk protein. During the desensitization phase, we will give increasing
      doses of cow's milk protein by mouth on a weekly basis, as tolerated. The desensitization
      protocol starts with dilutional doses of milk and build up to a goal of 8 ounces of cow's
      milk.

      Main Study Outcome Measure

      The percentage of children completing the desensitization protocol in each study group will
      be the primary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Completed Desensitization Protocol</measure>
    <time_frame>1 year</time_frame>
    <description>Subjects who withdrew prior to completing the desensitization protocol and those who experienced anaphylaxis during the desensitization protocol (i.e., were unable to complete the protocol) were considered to be &quot;treatment failures&quot;. Subjects who completed the desensitization protocol were considered to be &quot;treatment successes&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Milk Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Delayed Sensitivity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Sensitivity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Milk Oral Immunotherapy</intervention_name>
    <description>Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.</description>
    <arm_group_label>Delayed Sensitivity</arm_group_label>
    <arm_group_label>Immediate Sensitivity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Protein Powder</intervention_name>
    <description>Milk protein powder will be administered in incremental doses during the desensitization protocol.</description>
    <arm_group_label>Delayed Sensitivity</arm_group_label>
    <arm_group_label>Immediate Sensitivity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food Challenge</intervention_name>
    <arm_group_label>Delayed Sensitivity</arm_group_label>
    <arm_group_label>Immediate Sensitivity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be age six to 17 years and have a history of cow's milk allergy.
             Subjects shall maintain strict avoidance of consumption of all cow's milk protein
             containing foods.

          2. Subjects will have a history (within the past six months) of a positive skin prick
             test to milk extract or an immunocap IgE level greater than 0.35 kilounits per liter
             (kU/L), and a positive allergic reaction history to milk within the past 12 months.

          3. Subjects must be in good health, as determined by medical history and physical
             examination performed by a study physician.

          4. Females of childbearing potential must be using an effective method of contraception,
             including abstinence, and agree to continue to practice an acceptable method of
             contraception for the duration of their participation in the study.

          5. Informed consent of parent or legal guardian is required.

        Exclusion Criteria:

          1. Ability to tolerate eight ounces of cow's milk or eight grams of milk protein powder

          2. Pregnancy

          3. A history of soy allergy

          4. A history of food protein induced enterocolitis syndrome to milk

          5. A history of anaphylaxis requiring hospitalization

          6. A history of intubation related to asthma and/or a history of an intensive care unit
             admission for asthma management

          7. A current diagnosis of severe persistent asthma [forced expiratory volume in 1 second
             (FEV1) &lt; 60% of predicted, as defined by National Heart, Lung, and Blood Institute
             (NHLBI) guidelines, despite current therapy

          8. A current diagnosis of severe atopic dermatitis

          9. A serious chronic medical condition, including neurologic, hepatic, renal, endocrine,
             cardiovascular, gastrointestinal, pulmonary, or metabolic disease

         10. Use of oral or injection steroids within one month of protocol initial visit

         11. An acute illness within one week prior to the first dose of oral immunotherapy

         12. Use of antihistamines within seven days prior to double blind placebo controlled food
             challenge (DBPCFC)

         13. Use of chronic immunomodulatory therapy

         14. Participation in another experimental therapy study

         15. Participation in a study for the treatment of food allergy in the past 12 months

         16. Inability to discontinue antihistamines for skin testing and food challenges
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan M. Spergel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonella Cianferoni, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bollinger ME, Dahlquist LM, Mudd K, Sonntag C, Dillinger L, McKenna K. The impact of food allergy on the daily activities of children and their families. Ann Allergy Asthma Immunol. 2006 Mar;96(3):415-21.</citation>
    <PMID>16597075</PMID>
  </reference>
  <reference>
    <citation>Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, Matsui EC, Burks AW, Wood RA. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008 Dec;122(6):1154-60. doi: 10.1016/j.jaci.2008.09.030. Epub 2008 Oct 25.</citation>
    <PMID>18951617</PMID>
  </reference>
  <reference>
    <citation>Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, Ventura A. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008 Feb;121(2):343-7. Epub 2007 Dec 26.</citation>
    <PMID>18158176</PMID>
  </reference>
  <reference>
    <citation>Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy. 2004 Sep;59(9):980-7.</citation>
    <PMID>15291907</PMID>
  </reference>
  <reference>
    <citation>Zapatero L, Alonso E, Fuentes V, Mart√≠nez MI. Oral desensitization in children with cow's milk allergy. J Investig Allergol Clin Immunol. 2008;18(5):389-96.</citation>
    <PMID>18973104</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <results_first_submitted>April 22, 2015</results_first_submitted>
  <results_first_submitted_qc>May 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2015</results_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food hypersensitivity</keyword>
  <keyword>Milk hypersensitivity</keyword>
  <keyword>Milk allergy</keyword>
  <keyword>Food allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children with a history of cow's milk allergy were referred from CHOP Allergy Clinics located in the main campus and satellite offices. Allergy and general pediatric practices in the greater Philadelphia area were also contacted by study staff as part of enrollment outreach.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Delayed Sensitivity</title>
          <description>All subjects underwent a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder began build-up of desensitization during Week 16 and continued thru Week 50. Total active participation lasted 51 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Immediate Sensitivity</title>
          <description>All subjects underwent a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder began build-up of desensitization during Week 3 and continued thru Week 35. Total active participation lasted 38 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Delayed Sensitivity</title>
          <description>All subjects underwent a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder began build-up of desensitization during Week 16 and continued thru Week 50. Total active participation lasted 51 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Immediate Sensitivity</title>
          <description>All subjects underwent a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder began build-up of desensitization during Week 3 and continued thru Week 35. Total active participation lasted 38 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.25" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="B2" value="8.88" lower_limit="6" upper_limit="13"/>
                    <measurement group_id="B3" value="8.68" lower_limit="6" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Completed Desensitization Protocol</title>
        <description>Subjects who withdrew prior to completing the desensitization protocol and those who experienced anaphylaxis during the desensitization protocol (i.e., were unable to complete the protocol) were considered to be &quot;treatment failures&quot;. Subjects who completed the desensitization protocol were considered to be &quot;treatment successes&quot;.</description>
        <time_frame>1 year</time_frame>
        <population>The analysis population included all subjects who began desensitization per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Sensitivity</title>
            <description>All subjects underwent a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder began build-up of desensitization during Week 16 and continued thru Week 50. Total active participation lasted 51 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Immediate Sensitivity</title>
            <description>All subjects underwent a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder began build-up of desensitization during Week 3 and continued thru Week 35. Total active participation lasted 38 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Completed Desensitization Protocol</title>
          <description>Subjects who withdrew prior to completing the desensitization protocol and those who experienced anaphylaxis during the desensitization protocol (i.e., were unable to complete the protocol) were considered to be &quot;treatment failures&quot;. Subjects who completed the desensitization protocol were considered to be &quot;treatment successes&quot;.</description>
          <population>The analysis population included all subjects who began desensitization per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Safety was assessed at all follow-up clinic visits. Adverse events encountered during the previous week, as documented on subjects' event journals, were reviewed. Full physical exams performed and vital signs were obtained. During desensitization, families were contacted every other day (first week) and then twice a week (weeks 2-6).</desc>
      <group_list>
        <group group_id="E1">
          <title>Delayed Desensitization</title>
          <description>Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder (42 week protocol).</description>
        </group>
        <group group_id="E2">
          <title>Immediate Desensitization</title>
          <description>Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder (29 week protocol)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <description>3 subjects required epinephrine</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size constrains the statistical significance of this study. While useful in indicating potential trends, the results of this pilot study should be cautiously interpreted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rushani W. Saltzman MD</name_or_title>
      <organization>The Children's Hospital of Philadelphia</organization>
      <phone>215-590-2549</phone>
      <email>allergyandimmunology@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

